. 2016 Feb 19;7(14):18036–18049. doi: 10.18632/oncotarget.7495

Table 2. Clinical features with respect to the presence of MYC, BCL2 and BCL6 rearrangements.

Patients, No. (%)	MYC (n=15/206) Rearranged		BCL2 (n=36/187) Rearranged		BCL6 (n=51/171) Rearranged
Patients, No. (%)		P		P		P
Age, years
> 60	5 (36)	0.029	20 (62)	0.920	32 (65)	0.581
≤ 60	9 (64)	0.029	12 (38)	0.920	17 (35)	0.581
Ann Arbor stage
I-II	3 (21)	0.153	14 (44)	0.381	18 (37)	0.735
III-IV	11 (78)	0.153	18 (56)	0.381	30 (62)	0.735
LDH
Low	3 (23)	0.097	10 (38)	0.835	12 (30)	0.021
> upper limit of normal	10 (77)	0.097	16 (62)	0.835	28 (70)	0.021
Extranodal sites
≤ 1	5(35)	0.009	20 (74)	0.656	28 (72)	0.695
≥ 2	9(64)	0.009	7 (26)	0.656	11 (28)	0.695
ECOG †
PS ≤ 1	11(79)	0.473	8 (31)	0.780	25 (64)	0.659
PS > 1	3 (21)	0.473	8 (31)	0.780	14 (36)	0.659
IPI score ‡
Low (0-2)	4 (29)	0.051	19 (58)	0.268	24 (50)	0.533
High (3-5)	10 (71)	0.051	14 (42)	0.268	24 (50)	0.533

Abbreviations: IPI, International Prognostic Index; LDH, lactate dehydrogenase; †ECOG PS, ranging from 0 to 4, where a higher score indicates greater impairment. ‡ IPI score, ranging from 0 to 5, where 0 indicates the absence of prognostic factors, and 5 indicates the presence of all prognostic factors. The IPI score was stratified by the proposed RIPI score.